Characteristics of RCTs evaluating bevacizumab for indirect comparison.

NIAID Data Ecosystem2026-03-07 收录

数据链接：

https://figshare.com/articles/dataset/_Characteristics_of_RCTs_evaluating_bevacizumab_for_indirect_comparison_/268196 数据链接链接失效反馈

官方服务：

资源简介：

B: Bevacizumab, PDT: Photodynamic therapy, T: Triamcinolone.

创建时间：

2012-08-03

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

转移性结直肠癌真实世界研究

贝伐珠单抗疗效评估

This observational, multicenter, retrospective/prospective study will evaluate the use of Avastin (bevacizumab) in clinical practice in patients with metastatic colorectal cancer. Patients having init

NIAID Data Ecosystem80

Potential pre-BEV treatment predictors of overall survival in the patient recurrent high-grade glioma by BEV in Cox hazard model.

肿瘤生存预测

贝伐珠单抗疗效评估

Potential pre-BEV treatment predictors of overall survival in the patient recurrent high-grade glioma by BEV in Cox hazard model.

NIAID Data Ecosystem70

Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer

结直肠癌肝转移治疗

贝伐珠单抗疗效评估

The primary aim of this study is to investigate whether the addition of the new anti-cancer drug bevacizumab (Avastin) to the combination of the chemotherapeutic agents capecitabine (Xeloda) and oxali

NIAID Data Ecosystem50

Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab

转移性结直肠癌二线化疗

贝伐珠单抗疗效评估

RATIONALE: Drugs used in chemotherapy, such as irinotecan, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stoppi

NIAID Data Ecosystem70

ESSAI DE PHASE II RANDOMISE EVALUANT L’EFFICACITE DE SEQUENCES THERAPEUTIQUES ASSOCIANT FOLFIRI + BEVACIZUMAB ASSOCIEES OU NON AU MAINTIEN DU BEVACIZUMAB PENDANT LES INTERVALLES LIBRES DE CHIMIOTHERAPIE DANS LE CANCER COLO-RECTAL METASTATIQUE

转移性结直肠癌治疗

贝伐珠单抗疗效评估

Primary objectives: Taux de contrôle de la maladie à 12 mois (12 mois après randomisation) Primary endpoints: La Durée de Contrôle de la Maladie (DCM) est définie comme l’intervalle de temps entre la

NIAID Data Ecosystem50

Characteristics of RCTs evaluating bevacizumab for indirect comparison.

资源简介：

相关数据集